Compare AbCellera Biologics Inc (ABCL) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Sezzle Inc — how do they compare? AbCellera Biologics Inc trades at $10.32 (market cap $2.99B), while Sezzle Inc trades at $126 (market cap $4.32B). The key difference: Sezzle Inc is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Sezzle Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | SEZL | |
|---|---|---|
Market Cap | $2.99B | $4.32B |
Sector | Health | Technology |
52-Week High | $9.76 | $188.55 |
52-Week Low | $2.78 | $50.97 |
Enterprise Value | $2.58B | $4.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.
The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.
Sezzle (SEZL) trades at $125.44, up 6.31% in the past 24 hours, with a bearish technical signal but strong fundamentals including a 30.35% net income margin and consistent earnings beats. Recent Q2 2026 results showed revenue growth of 51.7% year-over-year to $149.7 million, with management raising full-year guidance for the third time in 2026, indicating robust operational momentum despite a recent stock decline.
The outlook is mixed: bullish fundamentals and analyst consensus support upside to a $158.29 price target, but technical indicators and valuation premiums pose risks. Key opportunities include subscriber growth and AI integration, while risks involve execution pressure and market volatility. Investors should weigh strong profitability against high P/E and P/S ratios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
